MMP2 and Cirrhosis: After erlotinib treatment, expression of antifibrotic pathways, including Mmp2, Mmp3, and Mmp8, were enhanced in PCLS from CDAHFD-induced cirrhosis, while expression of profibrotic pathways, including Mmp9 and Mmp13, were hampered.